메뉴 건너뛰기




Volumn 8, Issue 4, 2010, Pages 347-354

Susceptibility of HIV-1 to tipranavir and other antiretroviral agents in treatment-experienced patients: The UTILIZE study

Author keywords

Genotypic susceptibility; Phenotypic susceptibility; Protease inhibitor; Treatment experienced; Treatment failure

Indexed keywords

ABACAVIR; ADEFOVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZALCITABINE; ZIDOVUDINE;

EID: 77953481411     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016210791208677     Document Type: Article
Times cited : (3)

References (20)
  • 1
    • 33748116898 scopus 로고    scopus 로고
    • Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study
    • Palella FJ, Jr., Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27-34.
    • (2006) J Acquir Immune Defic Syndr , vol.43 , pp. 27-34
    • Palella Jr., F.J.1    Baker, R.K.2    Moorman, A.C.3
  • 2
    • 0038502358 scopus 로고    scopus 로고
    • Survival in an urban HIV-1 clinic in the era of highly active antiretroviral therapy: A 5-year cohort study
    • Lucas GM, Chaisson RE, Moore RD. Survival in an urban HIV-1 clinic in the era of highly active antiretroviral therapy: a 5-year cohort study. J Acquir Immune Defic Syndr 2003; 33: 321-8.
    • (2003) J Acquir Immune Defic Syndr , vol.33 , pp. 321-328
    • Lucas, G.M.1    Chaisson, R.E.2    Moore, R.D.3
  • 3
    • 0344760902 scopus 로고    scopus 로고
    • Panel on Antiretroviral Guidelines for Adults and Adolescents, Department of Health and Human Services. December 1, 1-161. Available at
    • Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 1-161. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
    • (2009) Guidelines For the Use of Antiretroviral Agents In HIV-1-infected Adults and Adolescents
  • 4
    • 34047207229 scopus 로고    scopus 로고
    • Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials
    • Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369: 1169-78.
    • (2007) Lancet , vol.369 , pp. 1169-1178
    • Clotet, B.1    Bellos, N.2    Molina, J.M.3
  • 5
    • 33746576313 scopus 로고    scopus 로고
    • Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1- infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: An analysis of combined data from two randomised open-label trials
    • Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1- infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006; 368: 466-75.
    • (2006) Lancet , vol.368 , pp. 466-475
    • Hicks, C.B.1    Cahn, P.2    Cooper, D.A.3
  • 6
    • 34247869104 scopus 로고    scopus 로고
    • Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs control protease inhibitor in the POWER and RESIST trials
    • Hill A, Moyle G. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs control protease inhibitor in the POWER and RESIST trials. HIV Med 2007; 8: 259-64.
    • (2007) HIV Med , vol.8 , pp. 259-264
    • Hill, A.1    Moyle, G.2
  • 7
    • 54849146700 scopus 로고    scopus 로고
    • Maraviroc for previously treated patients with R5 HIV-1 infection
    • Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359: 1429-41.
    • (2008) N Engl J Med , vol.359 , pp. 1429-1441
    • Gulick, R.M.1    Lalezari, J.2    Goodrich, J.3
  • 8
    • 52449097524 scopus 로고    scopus 로고
    • Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection
    • Montaner J, Yeni P, Clumeck NN, et al. Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection. Clin Infect Dis 2008; 47: 969-78.
    • (2008) Clin Infect Dis , vol.47 , pp. 969-978
    • Montaner, J.1    Yeni, P.2    Clumeck, N.N.3
  • 9
    • 47949114939 scopus 로고    scopus 로고
    • Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
    • Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359: 355-65.
    • (2008) N Engl J Med , vol.359 , pp. 355-365
    • Cooper, D.A.1    Steigbigel, R.T.2    Gatell, J.M.3
  • 10
    • 33847041109 scopus 로고    scopus 로고
    • Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1
    • Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007; 21: 395-402.
    • (2007) AIDS , vol.21 , pp. 395-402
    • Katlama, C.1    Esposito, R.2    Gatell, J.M.3
  • 11
    • 0038576281 scopus 로고    scopus 로고
    • Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America
    • Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348: 2175-85.
    • (2003) N Engl J Med , vol.348 , pp. 2175-2185
    • Lalezari, J.P.1    Henry, K.2    O'Hearn, M.3
  • 12
    • 0037849954 scopus 로고    scopus 로고
    • Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia
    • Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348: 2186-95.
    • (2003) N Engl J Med , vol.348 , pp. 2186-2195
    • Lazzarin, A.1    Clotet, B.2    Cooper, D.3
  • 13
    • 47949120697 scopus 로고    scopus 로고
    • Raltegravir with optimized background therapy for resistant HIV-1 infection
    • Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359: 339-54.
    • (2008) N Engl J Med , vol.359 , pp. 339-354
    • Steigbigel, R.T.1    Cooper, D.A.2    Kumar, P.N.3
  • 14
    • 0037040360 scopus 로고    scopus 로고
    • A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy
    • Cohen CJ, Hunt S, Sension M, et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002; 16: 579-88.
    • (2002) AIDS , vol.16 , pp. 579-588
    • Cohen, C.J.1    Hunt, S.2    Sension, M.3
  • 15
    • 0344593433 scopus 로고    scopus 로고
    • The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan
    • DeGruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000; 5: 41-8.
    • (2000) Antivir Ther , vol.5 , pp. 41-48
    • Degruttola, V.1    Dix, L.2    D'Aquila, R.3
  • 16
    • 38949152354 scopus 로고    scopus 로고
    • Highly active antiretroviral therapy- induced liver injury
    • Inductivo-Yu I, Bonacini M. Highly active antiretroviral therapy- induced liver injury. Curr Drug Saf 2008; 3: 4-13.
    • (2008) Curr Drug Saf , vol.3 , pp. 4-13
    • Inductivo-Yu, I.1    Bonacini, M.2
  • 18
    • 34347354196 scopus 로고    scopus 로고
    • Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double- blind, placebo-controlled trial
    • Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double- blind, placebo-controlled trial. Lancet 2007; 370: 39-48.
    • (2007) Lancet , vol.370 , pp. 39-48
    • Lazzarin, A.1    Campbell, T.2    Clotet, B.3
  • 19
    • 34347327010 scopus 로고    scopus 로고
    • Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double- blind, placebo-controlled trial
    • Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double- blind, placebo-controlled trial. Lancet 2007; 370: 29-38.
    • (2007) Lancet , vol.370 , pp. 29-38
    • Madruga, J.V.1    Cahn, P.2    Grinsztejn, B.3
  • 20
    • 38649088910 scopus 로고    scopus 로고
    • Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir
    • Lambert-Niclot S, Flandre P, Canestri A, et al. Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir. Antimicrob Agents Chemother 2008; 52: 491-6.
    • (2008) Antimicrob Agents Chemother , vol.52 , pp. 491-496
    • Lambert-Niclot, S.1    Flandre, P.2    Canestri, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.